MedPath

Study of the relationship between antiemetic effect of Aprepitant and plasma concentration of Aprepitant

Not Applicable
Conditions
Malignant tumor(esophageal cancer,gastric cancer etc.)
Registration Number
JPRN-UMIN000007048
Lead Sponsor
Toho University School of Pharmaceutical Sciences Department of Clinical Pharmaceutics
Brief Summary

o significant differences were found between the two groups in the percentage of CINV prevention. Of the 13 patients who experienced CINV, the highconcentration group showed a significant improvement in CINV during the aprepitant administration term.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1)Receiving an antiemetic drug 2)Receiving an opioid 3)Any patients judged by the investigator to be unfit to participate in the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath